Jade Biosciences, Inc. — Director's Dealing 2021

Jul 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aerovate Therapeutics, Inc. (AVTE)
CIK: 0001798749
Period of Report: 2021-07-15

Reporting Person: Dorval Allison (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-15	Stock Option (Right to Buy)	$14.82	A	25000	Acquired	2031-07-14	Common Stock (25000)	Direct

Footnotes

F1: This option shall vest in 36 substantially equal monthly installments, with the first installment vesting on August 15, 2021.